Skip to content
AnalystLens

METLIFE INCMET

Sector
Financial Services
Industry
Life Insurance
Exchange
NYSE

Stock Price $MET

Latest filings

You are here#31 of 58 in Financials by market cap

Filing record · 2016–202610-K1110-Q328-K249

MET filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 249 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Aug ’17Aug ’17
  2. Leadership change8-K · Mar ’19Mar ’19
  3. Material agreement8-K · Mar ’21Mar ’21
  4. Leadership change8-K · Jul ’25Jul ’25

01—Key figures

Share Class
Source: 10-KFY2025
Source: 10-KFY2025
Source: 10-KFY2025
Source: 10-KFY2025

Revenue Trend

Year-over-year comparison from 10-K annual reports

  19. $77.08B
YoY changeLargest recent move+9.0%in FY18Latest +8.6%

3 older moves run past ±20% (largest +34.4%); point at, tap or drag across the bars to read one.

Latest bar from 10-KFY2025Click a bar to open its SEC filing

View full history →
All MET Financial Metrics49 metrics

Income Statement12

Balance Sheet19

Cash Flow13

Per Share5

02—Overview

METLIFE INC Financial Overview 2021–2025

Updated Jul 10, 2026

MetLife’s net income collapsed from $1.6 billiona in Q1 2022 to a mere $14 million in Q1 2023, a sudden plunge that highlights the company's core investment thesis: management offsets severe derivative and investment portfolio volatility through aggressive capital returns and structural de-risking. Reflecting years of strategic run-offs and market friction, total assets contracted from $759.7 billion in FY2021 to $719.7 billion during FY2025. Despite this shrinking footprint, the company's outstanding shares steadily declined from 0.83 billion in FY2021 to 0.69 billion in FY2024, actively propping up equity value even as raw earnings per share fell from $7.65 to $5.94 over the same period.

To further isolate core operations from unhedged market noise, MetLife executed major risk-transfer transactions, highlighted by a $10 billionb reinsurance agreement with Chariot Reinsurance in 2025 to cede legacy annuity reserves. While quarterly GAAP results remained highly vulnerable to interest rate swings—such as a $1.7 billion net derivative loss in Q3 2025—underlying business performance proved resilient, with adjusted earnings holding firm at $1.6 billion that same quarter. Strategic acquisitions also diversified the revenue base, culminating in the purchase of PineBridge Investments in 2025 to significantly expand its asset management segment. The market rewarded this combination of balance sheet optimization and share reduction, valuing the stock at a close of $78.94 at the end of FY2025.

Recent Developments (Q4 2025 and Q1 2026)

MetLife carried strong operational momentum into 2026, highlighted by a jump in net income to $1.14 billionc for Q1 2026, up from $879 million in Q1 2025. Total revenues expanded to $19.07 billion, pushing adjusted earnings to $1.59 billion. This growth followed a strategic reorganization completed in Q4 2025 that established MetLife Investment Management as a distinct reporting segment. Management fortified the capital structure in February 2026 by issuing $1 billion in 5.850% subordinated debentures while executing $755 million in stock repurchases during the first quarter.

Bulls will champion the robust top-line growth and disciplined expense targets, making the stock look attractively priced at 13.3x earnings as of May 7, 2026. Conversely, bears might argue that heavy reliance on variable investment income—projected to drop to between $220 milliond and $270 million in Q2 2026—leaves overall margins exposed to macroeconomic headwinds.

What to watch: profitability metrics for the newly separated MetLife Investment Management segment; trajectory of variable investment yields against the $1.6 billione full-year target.

03—Filings

Recent SEC Filings

  1. 8-KMETLIFE INC 8-K Report, Regulation FD Disclosure (Sep 24, 2026)MetLife, Inc. has issued an 8-K filing to provide preliminary insights into its variable investment income for the third quarter of 2026, ahead of its official earnings release. The company estimates this income to be at least $600 million (pre-tax). This figure provides investors with an early indication of performance in key alternative investment areas, including private equity, real estate, and prepayment fees. While this disclosure offers a glimpse into a specific component of MetLife's revenue, it's crucial for investors to understand that these are preliminary, unaudited results. The company explicitly cautions that actual results may differ materially from these estimates. Investors should exercise caution and not rely solely on this information, as it is not a substitute for the full financial statements prepared under U.S. GAAP, which will be released on November 4, 2026.
  2. 8-KMETLIFE INC 8-K Report, Corporate Update (Aug 17, 2026)MetLife, Inc. (NYSE: MET) announced on August 17, 2026 that it has declared its third quarter 2026 preferred stock dividends across four series, as disclosed under Item 8.01 of this Form 8-K with the news release attached as Exhibit 99.1. The declarations cover the floating rate non-cumulative Series A (quarterly, $0.31471411 per share), the 5.875% fixed-to-floating Series D (semi-annual, $29.375 per share on $1,000 liquidation preference), the 5.625% Series E (quarterly, $0.3515625 per depositary share), and the 4.75% Series F (quarterly, $0.296875 per depositary share). All dividends are payable September 15, 2026, to holders of record as of August 31, 2026. This is a routine capital-management disclosure rather than a material operational or financial event. The filing contains no earnings data, guidance changes, balance sheet updates, or new capital actions such as issuances or repurchases. The dividends are non-cumulative, meaning MetLife has no obligation to pay missed amounts, so each declaration is a discretionary board decision that signals ongoing confidence in the company's capital position. For investors, the main takeaway is that MetLife continues to service its preferred capital stack on schedule, which supports the credit profile of these instruments and reflects the company's ongoing use of hybrid capital. Investors in the preferred securities should note the payment dates and record dates, while common shareholders will find little new information here beyond confirmation of the ongoing preferred capital structure.
  3. 8-KMETLIFE INC 8-K Report, Financial Results (Aug 5, 2026)MetLife reported second-quarter 2026 adjusted earnings of $1.573 billion, up 15% year over year, or $2.43 per diluted share, up 20%. Growth was driven by favorable underwriting and broad volume growth across segments. Group Benefits (+25%), Asia (+21%), and Latin America (+15%) led. Adjusted ROE was 17.0%, at the top of management's 15-17% target range. Reported GAAP net income rose only 1% to $705 million ($1.09 per share, up 6%). The gap reflects $428 million of pre-tax net investment losses and $772 million of pre-tax net derivative losses, which are excluded from adjusted earnings. Investors should therefore weigh the adjusted figures against the more volatile GAAP results. Top-line growth was solid. Premiums, fees and other revenues rose 7% to $13.7 billion, and adjusted PFOs excluding pension risk transfers (PRT) rose 5% to $13.0 billion. Net investment income rose 18% to $6.7 billion, but adjusted net investment income grew a more modest 7% to $5.6 billion. Variable investment income was $231 million, below the company's approximately $400 million quarterly target, reflecting lower private equity returns. The direct expense ratio was 12.1% excluding PRT and notable items, slightly above the prior-year 11.7% but on track to beat the full-year target. The reported expense ratio rose to 21.7% from 19.8%. Capital return was significant. MetLife returned over $1.1 billion to shareholders in the quarter through about $700 million of buybacks and about $400 million of dividends, and announced a new $3.0 billion repurchase authorization. Diluted share count fell to 646.9 million from 675.0 million, and book value per share rose 8% to $38.59. Adjusted book value per share rose only 3% to $57.71. Holding company cash and liquid assets were $3.4 billion, within the company's target range.
  4. 8-KMETLIFE INC 8-K Report, Regulation FD Disclosure (Jun 29, 2026)MetLife, Inc. (MET) has filed a Form 8-K to provide investors with preliminary insights into its variable investment income for the quarter ending June 30, 2026. The company estimates this income to be in the range of $220 million to $270 million (pre-tax). This preliminary figure offers a mid-quarter update ahead of the official earnings release scheduled for August 5, 2026, which will include the full quarterly financial supplement. This disclosure is important for investors tracking MetLife's diversified income streams, particularly those derived from private equity, real estate, and other funds, as well as prepayment fees. While this information is preliminary and unaudited, it provides a directional indication compared to the company's full-year 2026 guidance of approximately $1.6 billion (pre-tax) for variable investment income. Investors should exercise caution as actual results may differ materially, and this data should not replace the comprehensive financial statements.
  5. 8-KMETLIFE INC 8-K Report, Shareholder Vote Results (Jun 22, 2026)MetLife, Inc. (MET) reported the results of its annual meeting of common shareholders held on June 16, 2026. The filing indicates strong shareholder support for the company's governance and executive compensation practices. All eleven director nominees were elected, and the appointment of Deloitte & Touche LLP as the independent auditor for 2026 was ratified with a substantial majority of votes. Additionally, shareholders provided advisory approval for the compensation of Named Executive Officers, signaling confidence in the company's leadership and compensation structure. These results suggest a stable shareholder base that is largely aligned with the current board and management. The overwhelming support for director elections and auditor ratification underscores a healthy corporate governance framework. Investors can view these outcomes as positive indicators of continuity and trust in MetLife's operational and strategic direction.
View all 8-K filings →
View all filings (10-K, 10-Q, 8-K, proxy & more) →

04—See also

Related Companies

Annual revenue over each company’s last eight fiscal years, each strip on its own scale from zero.